These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35185467)

  • 1. Metabotropic Glutamate Receptor 5 Antagonism Reduces Pathology and Differentially Improves Symptoms in Male and Female Heterozygous zQ175 Huntington's Mice.
    Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
    Front Mol Neurosci; 2022; 15():801757. PubMed ID: 35185467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice.
    Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
    J Pharmacol Exp Ther; 2021 Oct; 379(1):74-84. PubMed ID: 34330748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mGluR5 antagonism increases autophagy and prevents disease progression in the
    Abd-Elrahman KS; Hamilton A; Hutchinson SR; Liu F; Russell RC; Ferguson SSG
    Sci Signal; 2017 Dec; 10(510):. PubMed ID: 29259100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease.
    Ibrahim KS; El Mestikawy S; Abd-Elrahman KS; Ferguson SSG
    J Neurosci; 2023 Jun; 43(23):4365-4377. PubMed ID: 37055181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington's pathology in zQ175 mice.
    Abd-Elrahman KS; Ferguson SSG
    Mol Brain; 2019 Apr; 12(1):35. PubMed ID: 30961637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Huntington's disease phenotype progression in male and female heterozygous FDNQ175 mice.
    Li SH; Colson TL; Chen J; Abd-Elrahman KS; Ferguson SSG
    Mol Brain; 2023 Sep; 16(1):67. PubMed ID: 37726802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
    Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
    Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mGluR5 regulates REST/NRSF signaling through N-cadherin/β-catenin complex in Huntington's disease.
    de Souza JM; Abd-Elrahman KS; Ribeiro FM; Ferguson SSG
    Mol Brain; 2020 Aug; 13(1):118. PubMed ID: 32859226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autophagy is increased following either pharmacological or genetic silencing of mGluR5 signaling in Alzheimer's disease mouse models.
    Abd-Elrahman KS; Hamilton A; Vasefi M; Ferguson SSG
    Mol Brain; 2018 Apr; 11(1):19. PubMed ID: 29631635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of miR-132/212 deficiency in the zQ175 mouse model of Huntington's disease.
    Nateghi B; Keraudren R; Boulay G; Bazin M; Goupil C; Canet G; Loiselle A; St-Amour I; Planel E; Soulet D; Hébert SS
    Front Neurosci; 2024; 18():1421680. PubMed ID: 39170678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mGluR5 Allosteric Modulation Promotes Neurorecovery in a 6-OHDA-Toxicant Model of Parkinson's Disease.
    Farmer K; Abd-Elrahman KS; Derksen A; Rowe EM; Thompson AM; Rudyk CA; Prowse NA; Dwyer Z; Bureau SC; Fortin T; Ferguson SSG; Hayley S
    Mol Neurobiol; 2020 Mar; 57(3):1418-1431. PubMed ID: 31754998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking glutamate mGlu
    Milanese M; Bonifacino T; Torazza C; Provenzano F; Kumar M; Ravera S; Zerbo AR; Frumento G; Balbi M; Nguyen TPN; Bertola N; Ferrando S; Viale M; Profumo A; Bonanno G
    Br J Pharmacol; 2021 Sep; 178(18):3747-3764. PubMed ID: 33931856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive deficits in transgenic and knock-in HTT mice parallel those in Huntington's disease.
    Farrar AM; Murphy CA; Paterson NE; Oakeshott S; He D; Alosio W; McConnell K; Menalled LB; Ramboz S; Park LC; Howland D; Brunner D
    J Huntingtons Dis; 2014; 3(2):145-58. PubMed ID: 25062858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease.
    Peng Q; Wu B; Jiang M; Jin J; Hou Z; Zheng J; Zhang J; Duan W
    PLoS One; 2016; 11(2):e0148839. PubMed ID: 26859386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabotropic glutamate receptor 5 as a potential therapeutic target in Huntington's disease.
    Ribeiro FM; Hamilton A; Doria JG; Guimaraes IM; Cregan SP; Ferguson SS
    Expert Opin Ther Targets; 2014 Nov; 18(11):1293-304. PubMed ID: 25118797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
    Ma Q; Yang J; Li T; Milner TA; Hempstead BL
    Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease.
    Ribeiro FM; Devries RA; Hamilton A; Guimaraes IM; Cregan SP; Pires RG; Ferguson SS
    Hum Mol Genet; 2014 Apr; 23(8):2030-42. PubMed ID: 24282028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive Training at a Young Age Attenuates Deficits in the zQ175 Mouse Model of HD.
    Curtin PC; Farrar AM; Oakeshott S; Sutphen J; Berger J; Mazzella M; Cox K; He D; Alosio W; Park LC; Howland D; Brunner D
    Front Behav Neurosci; 2015; 9():361. PubMed ID: 26793080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease.
    Heikkinen T; Lehtimäki K; Vartiainen N; Puoliväli J; Hendricks SJ; Glaser JR; Bradaia A; Wadel K; Touller C; Kontkanen O; Yrjänheikki JM; Buisson B; Howland D; Beaumont V; Munoz-Sanjuan I; Park LC
    PLoS One; 2012; 7(12):e50717. PubMed ID: 23284644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175.
    Menalled LB; Kudwa AE; Miller S; Fitzpatrick J; Watson-Johnson J; Keating N; Ruiz M; Mushlin R; Alosio W; McConnell K; Connor D; Murphy C; Oakeshott S; Kwan M; Beltran J; Ghavami A; Brunner D; Park LC; Ramboz S; Howland D
    PLoS One; 2012; 7(12):e49838. PubMed ID: 23284626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.